TABLE 4.

Recovery of basal dendritic growth.

(A) Pyramidal cells treated with ifenprodil from DIV 7–10 followed by recovery until DIV 15
	Pyramidal cells of layers II/III		Pyramidal cells of layers V/VI
Condition (no. of batches)	ADL (n) Segments	BDL Segments	ADL (n) Segments	BDL Segments
Control	1526 ± 92 (36) 28 ± 1.9	308 ± 20 6.2 ± 0.5	1394 ± 80 (26) 26 ± 1.4	345 ± 32 6.9 ± 0.6
Ifenprodil (2)	1601 ± 106 (25) 29 ± 2.1	336 ± 31 7.3 ± 0.8	1303 ± 116 (20) 25 ± 1.9	284 ± 23 5.7 ± 0.5
Mann–Whitney test vs. control	P = 0.49 P = 0.63	P = 0.73 P = 0.1	P = 0.35 P = 0.62	P = 0.32 P = 0.2
(B) Interneurons treated with ifenprodil from DIV 7–10 followed by recovery until DIV 15
Condition (no. of batches)	MDL (n)	MDS		no. of PD
Control	549 ± 45 (26)	7.2 ± 0.6		5.7 ± 0.3
Ifenprodil (2)	525 ± 45 (24)	9.3 ± 0.8		4.7 ± 0.4
Mann–Whitney test vs. control	P = 0.68	P = 0.11		P = 0.02

Ifenprodil was applied at DIV 6 and DIV 8, and at DIV 10 OTC were switched to medium without antagonist until analysis at DIV 15. Length and branching of dendrites of pyramidal cells (A) and of interneurons (B) were no longer different from control cells. The weak significance for the number of primary dendrites is presumably due to sampling; primary dendrites had never been different in the other experiments. Given is the mean ± S.E.M, and, in italics, the p-values of the Mann–Whitney rank sum test. For pyramidal cells in (A): ADL, apical dendritic length [μm]; BDL, the average basal dendritic length per cell [μm]; the number of dendritic segments; for interneurons in (B): MDL, mean dendritic length [μm] per cell; MDS, mean dendritic segments; no. of PD, number of primary dendrites; n, number of neurons analyzed.